Long‐term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia

Lenalidomide is effective against relapsed chronic lymphocytic leukemia ( CLL ). We report the first case of long‐term molecular remission with continuous lenalidomide treatment in a young patient with CLL relapsed to multiple treatments. Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient‐specific primers. A 20‐yr‐old patient with standard‐risk CLL was treated with lenalidomide after multiple relapses and achieved a 4 yr long complete molecular response with minimal toxicities. Published biologic data support that lenalidomide induces an immune‐mediated control of CLL , and our case suggests that long‐term treatment with lenalidomide is effective at a molecular level in patients with relapsed CLL .